Novo Nordisk Shares Sink After Sales Outlook Misses As US GLP-1 Competition Intensifies Novo Nordisk ADRs were clubbed like a baby seal around midday after the Danish drugmaker said in an early full-year outlook release that it expects sales to shrink 5% to 13% at constant exchange rates, far worse than the expected 1.3% decline Wall Street analysts had been expecting, according to Bloomberg consensus. Here’s a snapshot of the full year forecast (courtesy of Bloomberg): Sees sales at constant exchange rates -5% to -13%, estimate -1.39% (Bloomberg Consensus) Sees operating profit at constant FX -5% to -13%, estimate -3.12%… — Continue at ZeroHedge News : Read More
